Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Age-Related Macular Degeneration
Last updated March 27, 2015
Status:
Concluded with an LOI
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Chronic Hepatitis C
Last updated March 3, 2015
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Metastatic Pancreatic Cancer
Last updated March 2, 2015
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Advanced Melanoma, first-line
Last updated March 2, 2015
Status:
Negotiations were not pursued
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Last updated February 27, 2015
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Rheumatoid Arthritis, Ulcerative Colitis and Crohn's Disease
Last updated February 23, 2015
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Chronic Hepatitis C
Last updated February 5, 2015
Harvoni (ledipasvir/sofosbuvir)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Chronic Hepatitis C
Last updated February 5, 2015
Breo Ellipta (fluticasone furoate/vilanterol)
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated February 3, 2015
Advair (salmeterol xinafoate/fluticasone propionate)
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD) and Asthma
Last updated February 3, 2015